跳至主要内容
临床试验/NCT06840990
NCT06840990已完成不适用

Ophthalmic Solution in Corneal Re-epithelization

D&V FARMA srl1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
1
主要终点
Corneal re-ephitalization

研究概览

简要总结

Data analyses and revision of the corneal re-epithelization in patients who underwent either PRK (Photorefractive Keratectomy), CXL (Corneal Cross-Linking), PTK (phototherapeutic keratectomy), or experienced a corneal abrasion. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market. Both molecules have been widely studied for their wound healing properties in the ophtalmic field. This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients who had undergone surgical procedures involving de-epithelialization, which included CXL, PRK, and PTK, as well as those with a first diagnosis of corneal abrasion

排除标准

  • •patients with known allergies or hypersensitivity to any components of the tested formulations or standard therapies, or those requiring different treatments compared to the rest of the study population

结局指标

主要结局

Corneal re-ephitalization

时间窗: 2 WEEKS

To evaluate and follow the corneal re-ephitalization process a topograph measuring epithelium thickness will be used.

次要结局

未报告次要终点

研究者

发起方
D&V FARMA srl
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验